Navigating New Treatment Options in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EP. 1: Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

EP. 2: Front-Line Treatment of DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

January 24th 2022

Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.

EP. 3: Relapsed and Refractory Diffuse Large B-Cell Lymphoma

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

January 24th 2022

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.

EP. 4: Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

ByKami J. Maddocks, MD,Jason Westin, MD,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD,David Miklos, MD, Stanford University

February 3rd 2022

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

EP. 5: CAR-T Therapy

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 3rd 2022

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

EP. 6: CAR-T Therapies in R/R DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

EP. 7: Safety With CAR-T Therapies in R/R DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

EP. 8: Real-World Data With CAR-T Therapies in R/R DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 17th 2022

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

EP. 9: Monoclonal Antibodies for Treatment of R/R DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 17th 2022

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

EP. 10: Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Richard T. Maziarz, MD,Grzegorz S. Nowakowski, MD

February 24th 2022

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

EP. 11: Concluding Thoughts on the DLBCL Treatment Landscape

ByKami J. Maddocks, MD,Jason Westin, MD,David Miklos, MD, Stanford University,Grzegorz S. Nowakowski, MD,Richard T. Maziarz, MD

February 24th 2022

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Navigating New Treatment Options in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EP. 1: Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

EP. 2: Front-Line Treatment of DLBCL

EP. 3: Relapsed and Refractory Diffuse Large B-Cell Lymphoma

EP. 4: Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

EP. 5: CAR-T Therapy

EP. 6: CAR-T Therapies in R/R DLBCL

EP. 7: Safety With CAR-T Therapies in R/R DLBCL

EP. 8: Real-World Data With CAR-T Therapies in R/R DLBCL

EP. 9: Monoclonal Antibodies for Treatment of R/R DLBCL

EP. 10: Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

EP. 11: Concluding Thoughts on the DLBCL Treatment Landscape

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL